Efficacy and safety on estrogen/androgen therapy: Menopausal symptoms, bone, and cardiovascular parameters

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 43, Issue 8 SUPPL., 1998, Pages 746-752

  Barrett connor, Elizabeth ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Androgens; Estrogen androgen therapy; Estrogens; Postmenopausal hormone replacement therapy

Indexed keywords

ANDROGEN; CONJUGATED ESTROGEN; ESTRADIOL; ESTRATEST; ESTROGEN; ESTRONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHYLTESTOSTERONE; PRASTERONE SULFATE; UNCLASSIFIED DRUG;

ACNE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; ESTROGEN THERAPY; HEART PROTECTION; HIRSUTISM; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; LIPID METABOLISM; MENOPAUSAL SYNDROME; NAUSEA; ORAL DRUG ADMINISTRATION; OVARIECTOMY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL;

ADULT; ANDROGENS; BONE DENSITY; CARDIOVASCULAR DISEASES; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; OVARIECTOMY; PATIENT SELECTION;

EID: 0031753859     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (28)

1. Troy SM, Hicks DR, Parker VD, Jusko WJ, Rofsky HE, Porter RJ: Differences in pharmacokinetics and comparative bioavailability between Premarin® and Estratab® in healthy postmenopausal women. Curr Ther Res 1994;55:359-372
2. Geist SH, Salmon UJ: Androgen therapy in gynecology. JAMA 1941;117:2207-2213
3. Kurzrok L, Rothbart H: Treatment of female menopause with methyltestosterone and stilbestrol. Am J Surg 1942;LVI: 636-639
4. Greenblatt RB, Barfield WE, Garner JF, Calk GL, Harrod JP Jr: Evaluation of an estrogen, androgen, estrogen-androgen combination, and a placebo in the treatment of the menopause. Comparison of Treatments for Menopause 1950;10:1547-1558
5. Glass SJ, Shapiro MR: Androgen-estrogen treatment in the menopause. GP 1951;III:39-42
6. Birnberg CH, Kurzrok R: Low-dosage androgen-estrogen therapy in the older age group. Androgen-Estrogen Therapy in the Elderly 1955;3:656-666
7. 4-androstenedione, testosterone and methyltestosterone. Acta Med Scand 1959;165: 459-466
8. Kupperman HS, Wetchler BB, Blatt MHG: Contemporary therapy of the menopausal syndrome. JAMA 1959;171: 103/1627-110/1634
9. Cardozo L, Gibb DM, Tuck SM, Thom MH, Studd JW, Cooper DJ: The effects of subcutaneous hormone implants during climacteric. Maturitas 1984;5:177-184
10. Burger HG, Hailes J, Menelaus M, Nelson J, Hudson B, Balazs N: The management of persistent menopausal symptoms with oestradiol-testosterone implants: Clinical, lipid and hormonal results. Maturitas 1984;6:351-358
11. Farish E, Fletcher CD, Hart DM, Assawi FA, Abdalla HI, Gray CE: The effects of hormone implants on serum lipoproteins and steroid hormones in bilaterally oophorectomised women. Acta Endocrinol (Copenh) 1984;106;116-120
12. Sherwin BB: Changes in sexual behavior as a function of plasma sex steroid levels in post-menopausal women. Maturitas 1985;7:225-233
13. Sherwin BB, Gelfand MM, Brender W: Androgen enhances sexual motivation in females: A prospective, crossover study of sex steroid administration in the surgical menopause. Psychosom Med 1985;47:339-351
14. Sherwin BB, Gelfand MM: Differential symptom response to parenteral estrogen and/or androgen administration in the surgical menopause. Am J Obstet Gynecol 1985;151:153-160
15. Sherwin BB, Gelfand MM: The role of androgen in the maintenance of sexual functioning in oophorectomized women. Psychosom Med 1987;49:397-409
16. Gelfand MM, Ferenczy A, Bergeron C: Endometrial response to estrogen-androgen stimulation. In Menopause: Evaluation, Treatment, and Health Concerns. New York, Alan R. Liss, Inc, 1989, pp 29-40
17. Myers LS, Dixen J, Morrissette D, Carmichael M, Davidson JM: Effects of estrogen, androgen, and progestin on sexual psychophysiology and behavior in postmenopausal women. J Clin Endocrinol Metab 1990;70:1124-1131
18. Gambrell RD Jr, Teran AZ: Changes in lipids and lipoproteins with long-term estrogen deficiency and hormone replacement therapy. Am J Obstet Gynecol 1991;165:307-315
19. Savvas M, Studd JW, Norman S, Leather AT, Garnett TJ, Fogelman I: Increase in bone mass after one year of percutaneous oestradiol and testosterone implants in postmenopausal women who have previously received long-term oral oestrogens. Br J Obstet Gynaecol 1992;99: 757-760
20. Hickok LR, Toomey C, Speroff L: A comparison of esterified estrogens with and without methyltestosterone: Effects on endometrial histology and serum lipoproteins in postmenopausal women. Obstet Gynecol 1993;82:919-924
21. Erdtsieck RJ, Pols HA, van Kuijk C, et al: Course of bone mass during and after hormonal replacement therapy with and without addition of nandrolone decanoate. J Bone Miner Res 1994;9:277-283
22. Watts NB, Notelovitz M, Timmons MC, Addison WA, Wiita B, Downey LJ: Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause. Obstet Gynecol 1995;85:529-537
23. Raisz LG, Wiita B, Artis A, et al: Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. J Clin Endocrinol Metab 1996,81:37-43
24. Davis SR, McCloud P, Strauss BJ, Burger H: Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 1995;21:227-236
25. Barrett-Connor E, Timmons C, Young R, Wiita B, Estratest Working Group: Interim safety analysis of a two-year study comparing oral estrogen-androgen and conjugated estrogens in surgically menopausal women. J Women's Health 1996;5:593-602
26. Young R, Barrett-Connor E, Grimm R, et al: Increased bone mineral density in surgically menopausal women treated with oral estrogen-androgen: A two-year double-blind study comparing two doses each of conjugated estrogens and estrogen-androgen (poster). Presented at a meeting of the American Society for Reproductive Medicine, Cincinnati, October 1997
27. Genant HK, Lucas J, Weiss S, et al: Low-dose esterified estrogen therapy: Effects on bone, plasma, estradiol, endometrium, and lipids. Arch Intern Med 1997;157:2609-2615
28. Phillips E, Bauman C: Safety surveillance of esterified estrogens - methyltestosterone (Estratest® and Estratest® HS) replacement therapy in the United States. Clin Ther 1997;19: 1070-1084